Not applicableUnknownNCT03764917What this trial is testingNGS Combined With RNAseq on Tumor Immune Escape in NSCLCWho this might be right forNon-small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableStudy completedNCT06686602What this trial is testingA Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast CancerWho this might be right forAdvanced/Metastatic NSCLCAdvanced/Metastatic HER2-negative Breast Cancer Daiichi Sankyo 13,759
Early research (Phase 1)WithdrawnNCT05905341What this trial is testingStudy of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Who this might be right forBreast CancerOvarian CancerLiposarcoma+3 more Pfizer
Large-scale testing (Phase 3)Ended earlyNCT04427072What this trial is testingStudy of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationWho this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 22
Not applicableStudy completedNCT03944265What this trial is testingGenetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung CancerWho this might be right forActivating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more Thomas Jefferson University 14
Testing effectiveness (Phase 2)Study completedNCT04677595What this trial is testingStudy of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Novartis Pharmaceuticals 37
Early research (Phase 1)Study completedNCT01520389What this trial is testingSafety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentWho this might be right forAdvanced Solid TumorsColorectal CancerSquamous Cell Head and Neck Cancer+2 more Merrimack Pharmaceuticals 112
Not applicableNot Yet RecruitingNCT07191405What this trial is testingClinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid TumorsWho this might be right forImmunotherapyChemotherapy Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)WithdrawnNCT04464967What this trial is testingSafety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWho this might be right forAdvanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more NKGen Biotech, Inc.
Large-scale testing (Phase 3)Study completedNCT01951482What this trial is testingPemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung CancerWho this might be right forNon Squamous Non-small Cell Lung CancerBrain MetastasesBevacizumab Sun Yat-sen University 160
Early research (Phase 1)Study completedNCT03516214What this trial is testingEGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsWho this might be right forBronchial Neoplasms University of Cologne 18
Testing effectiveness (Phase 2)Looking for participantsNCT07070232What this trial is testingA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsWho this might be right forAdvanced Solid Tumor BioNTech SE 980
Testing effectiveness (Phase 2)UnknownNCT05675033What this trial is testingSerplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaWho this might be right forLung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 Inhibitor+1 more Fujian Cancer Hospital 50
Early research (Phase 1)Active Not RecruitingNCT03611738What this trial is testingCeritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCWho this might be right forNon-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer Metastatic+3 more H. Lee Moffitt Cancer Center and Research Institute 21
Testing effectiveness (Phase 2)Looking for participantsNCT06277674What this trial is testingEfficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIWho this might be right forNon-small Cell Lung Cancer Guangzhou University of Traditional Chinese Medicine 20
Testing effectiveness (Phase 2)UnknownNCT03765775What this trial is testingAnlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NegativeWho this might be right forCarcinomaNon-small Cell Lung CancerLung Neoplasm First Hospital of Shijiazhuang City 20
Testing effectiveness (Phase 2)Study completedNCT03647488What this trial is testingStudy of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT03513666What this trial is testingToripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI TreatmentWho this might be right forNSCLC Shanghai Junshi Bioscience Co., Ltd. 40
Testing effectiveness (Phase 2)Looking for participantsNCT05579366What this trial is testingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Who this might be right forHigh Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more Genmab 764
Not applicableUnknownNCT03564197What this trial is testing18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCWho this might be right forNSCLC Stage IV The Netherlands Cancer Institute 80